July 14th 2025
FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.
Impact of Effective BP Control in Reducing CV Risk in Patients with Obesity & HTN
November 20th 2023Patients with obesity and hypertension need to be aggressively treated in order to decrease their risk of cardiovascular complications, says Dr Jonathan Parker, President of the Alabama Obesity Society.